Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Updated: Capricor’s drug for Duchenne muscular dystrophy was not approved by the FDA, stock price plummets

Updated: Capricor’s drug for Duchenne muscular dystrophy was not approved by the FDA, stock price plummets

路透社路透社2026/11/21 01:31
Show original

Capricor's response has been added in paragraphs 3 and 6

- The U.S. Food and Drug Administration (FDA) said on Friday it had rejected Capricor Therapeutics' experimental cell therapy CAPR.O for a fatal genetic disease that causes muscle degeneration, adding to the string of regulatory setbacks faced by the biotechnology company.

The company had been seeking approval for the therapy, called deramiocel, intended to preserve upper limb function in patients with Duchenne muscular dystrophy.

Capricor's stock plunged 77% in after-hours trading, and the company criticized the decision. CEO Linda Marban said, "The FDA has let down the Duchenne muscular dystrophy patient community," calling the rejection "groundless."

The agency said there were serious data integrity issues in a key clinical trial, including unauthorized changes to the analysis plan after the trial began, violations of rules designed to ensure patients and researchers did not know who received the treatment, and other breaches of the trial protocol.

The FDA stated these protocol violations "undermine the reliability of the study data." The agency added that this amounted to evidence the data "cannot be considered reliable or interpretable" and could not demonstrate the therapy’s effectiveness. The FDA also noted the therapy failed to meet the study’s primary goal.

CEO Marban said Capricor stands by its data, which she said had been independently validated before the July advisory committee meeting. "It is irresponsible for the FDA to ignore this, and families of Duchenne muscular dystrophy patients will bear the consequences," she said in a statement to Reuters.

Duchenne muscular dystrophy is a fatal genetic disease that primarily affects boys, causing progressive muscle weakness, loss of mobility, heart complications, and early death.

The regulatory rejection is a heavy blow to Capricor, threatening not only its flagship experimental asset but also casting doubt on the company's commercial prospects after months of effort—including narrowing the therapeutic focus to arm and hand function in order to salvage the application.

Previously, in July, the FDA advisory committee voted 9 to 3 (link) that the evidence presented at the time did not support deramiocel's effectiveness in treating Duchenne-related cardiomyopathy.

In August, Capricor submitted a revised application (link) containing 24-month data from its late-stage clinical trial and additional analyses focused on upper limb muscle function.


(To aid non-native English speakers, Reuters provides automated translations of its coverage into several other languages. Because automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text. The translations are provided solely for the convenience of readers. Reuters accepts no liability for any damage or loss arising from the use of automated translations.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16